CEP350 and Miyoshi myopathy: In a cohort of 654 MM patients from the GMMG HD4 and MM5 studies [23], however, low CEP350 expression levels were associated with significantly better progression-free (p < 0.01) and overall survival (p = 0.02) (Fig. 5A, Supplementary Fig. S2).